Next Article in Journal
Biosynthesis of Polyunsaturated Fatty Acids in Marine Invertebrates: Recent Advances in Molecular Mechanisms
Previous Article in Journal
Reporter Dyes Demonstrate Functional Expression of Multidrug Resistance Proteins in the Marine Flatworm Macrostomum lignano: The Sponge-Derived Dye Ageladine A Is Not a Substrate of These Transporters
Article Menu

Export Article

Mar. Drugs 2013, 11(10), 3970-3997; doi:10.3390/md11103970

Dithiolopyrrolone Natural Products: Isolation, Synthesis and Biosynthesis
Zhiwei Qin 1,2, Sheng Huang 1, Yi Yu 1,* and Hai Deng 2,*
Key Laboratory of Combinatory Biosynthesis and Drug Discovery (Ministry of Education), School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China
Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 3UE, Scotland, UK
Authors to whom correspondence should be addressed; Tel.: +86-027-68752491 (Y.Y.); Fax: +86-27-68759850 (Y.Y.); Tel.: +44-1224-272953 (H.D.); Fax: +44-1224-272921 (H.D.).
Received: 30 July 2013; in revised form: 25 September 2013 / Accepted: 26 September 2013 / Published: 17 October 2013


: Dithiolopyrrolones are a class of antibiotics that possess the unique pyrrolinonodithiole (4H-[1,2] dithiolo [4,3-b] pyrrol-5-one) skeleton linked to two variable acyl groups. To date, there are approximately 30 naturally occurring dithiolopyrrolone compounds, including holomycin, thiolutin, and aureothricin, and more recently thiomarinols, a unique class of hybrid marine bacterial natural products containing a dithiolopyrrolone framework linked by an amide bridge with an 8-hydroxyoctanoyl chain linked to a monic acid. Generally, dithiolopyrrolone antibiotics have broad-spectrum antibacterial activity against various microorganisms, including Gram-positive and Gram-negative bacteria, and even parasites. Holomycin appeared to be active against rifamycin-resistant bacteria and also inhibit the growth of the clinical pathogen methicillin-resistant Staphylococcus aureus N315. Its mode of action is believed to inhibit RNA synthesis although the exact mechanism has yet to be established in vitro. A recent work demonstrated that the fish pathogen Yersinia ruckeri employs an RNA methyltransferase for self-resistance during the holomycin production. Moreover, some dithiolopyrrolone derivatives have demonstrated promising antitumor activities. The biosynthetic gene clusters of holomycin have recently been identified in S. clavuligerus and characterized biochemically and genetically. The biosynthetic gene cluster of thiomarinol was also identified from the marine bacterium Pseudoalteromonas sp. SANK 73390, which was uniquely encoded by two independent pathways for pseudomonic acid and pyrrothine in a novel plasmid. The aim of this review is to give an overview about the isolations, characterizations, synthesis, biosynthesis, bioactivities and mode of action of this unique family of dithiolopyrrolone natural products, focusing on the period from 1940s until now.
dithiolopyrrolone natural products; chemical isolation; total synthesis; biosynthesis; mode of action

1. Introduction

There is an urgent need for new antibiotics with novel cellular targets. Though resistance to existing antibiotics is increasing at an alarming rate, only four new structural classes of antibiotics have been introduced to the clinic in the last 50 years [1,2,3]. Dithiolopyrrolones are a group of potent antibiotic natural products that have been found in both Gram-negative and Gram-positive bacteria. They consist of a unique pyrrolinonodithiole (4H-[1,2] dithiolo [4,3-b] pyrrol-5-one) chromophore [4]. Since the isolation of the first member of this family aureothricin (1) from a soil bacterium Streptomyces sp. 26A over 65 years ago [5], this class of molecules has intrigued numerous research groups not only for their unique chemical structures and their antibacterial/antifungal activities but also the chemical logic and regulation of the biosynthesis. Many members of this family have already showed strong broad-spectrum activities towards Gram-positive and Gram-negative bacteria, Yeast, Fungi and even parasites [6]. Holomycin (9) appeared to inhibit the rafamycin-resistant bacteria. It also acts as antibacterial agent toward clinical pathogen methicillin-resistant Staphylococcus aureus N315. Its mode of action has been long attributed to inhibit the activity of bacterial RNA polymerase although the exact mechanism remained to be elucidated in vitro. In the last two decades, there has been an increasing interest in both synthetic and pharmacological investigations of this unique class of molecules due to the emerging significance of aryl-containing dithiolopyrrolone as antiproliferative agents [7].

Despite increasing attention in this rare class of antibiotic natural products, there has been no literature to summarize and critically evaluate the scientific conclusions throughout the studies on dithiolopyrrolones. This review will give an overview about the discovery and bioactivity, synthesis and biosynthesis of this family of rare natural products, covering the period since 1948. Table 1 provides a summary of the structures of naturally occurring dithiolopyrrolones that were identified so far.

Table 1. A summary of naturally occurring dithiolopyrrolone antibiotics. Marinedrugs 11 03970 i001
Table 1. A summary of naturally occurring dithiolopyrrolone antibiotics. Marinedrugs 11 03970 i001
1AureothricinCH3CH2COHCH3Streptomyces sp. 26A[5]
2ThiolutinCH3COHCH3Streptomyces albus[6]
3Isobutanoylpyrrothine(CH3)2CHCOHCH3Saccharothrix algeriensis[8]
4ButanoylpyrrothineCH3(CH2)2COHCH3Saccharothrix algeriensis[9,10]
5Senecioylpyrrothine(CH3)2C=CHCOHCH3Saccharothrix algeriensis[9,10]
6Tigloylpyrrothine(CH3)CH=C(CH3)COHCH3Saccharothrix algeriensis[9,10]
7Xenorhabdin 4CH3(CH2)4COHCH3Xenorhabdus nematophilus XQ1 (ATCC 39497)[11]
8Xenorhabdin 5(CH3)2CH(CH2)3COHCH3Xenorhabdus nematophilus XQ1 (ATCC 39497)[11]
9HolomycinCH3COHHStreptomyces griseus (NRRL 2764)[12]
10N-PropanoylholothineCH3CH2COHHStreptomyces sp. P662[13]
11vD844CHOCH3HActinomycete sp.[14]
12Xenorhabdin 1CH3(CH2)4COHHXenorhabdus nematophilus XQ1 (ATCC 39497)[11]
13Xenorhabdin 2(CH3)2CH(CH2)3COHHXenorhabdus nematophilus XQ1 (ATCC 39497)[11]
14Xenorhabdin 3CH3(CH2)6COHHXenorhabdus nematophilus XQ1 (ATCC 39497)[11]
15Xenorhabdin 8decanoylHHPseudoalteromonas sp. SANK 73390[15]
16Xenorhabdin 9dodecanoylHHPseudoalteromonas sp. SANK 73390[15]
17Xenorhabdin 10E-dec-3-enoylHHPseudoalteromonas sp. SANK 73390[15]
18Xenorhabdin 11Z-dec-4-enoylHHPseudoalteromonas sp. SANK 73390[15]
19Xenorhabdin 12E-tetradecenoylHHPseudoalteromonas sp. SANK 73390[15]
20Xenorhabdin 13Z-hexadecenoylHHPseudoalteromonas sp. SANK 73390[15]
21Thiomarinol AMarinolic acids AHHPseudoalteromonas sp. SANK 73390[16]
22Thiomarinol BMarinolic acids BHHPseudoalteromonas sp. SANK 73390[17]
23Thiomarinol CMarinolic acids CHHPseudoalteromonas sp. SANK 73390[17]
24Thiomarinol DMarinolic acids DHHPseudoalteromonas sp. SANK 73390[18]
25Thiomarinol EMarinolic acids EHHPseudoalteromonas sp. SANK 73390[18]
26Thiomarinol FMarinolic acids FHHPseudoalteromonas sp. SANK 73390[18]
27Thiomarinol GMarinolic acids GHHPseudoalteromonas sp. SANK 73390[18]

2. Isolation and Characterization

The family of dithiolopyrrolonenatural products can be divided into three subfamilies: N-methyl, N-acylpyrrothine (thiolutin type), N-acylpyrrothine (holomycin type) and thiomarinol, a distinct group of PKS-NRPS hybrid antibiotics. In this section, the isolation and structural elucidation will be summarized.

2.1. N-Methyl, N-Acylpyrrothine (Thiolutin-Type) Derivatives

The first dithiolopyrrolone natural product, aureothricin (1), was reported in 1948 (Figure 1) [5]. Umezawa and co-workers isolated a new strain Streptomyces sp. 26A from a soil sample, collected in Mitaka Tokyo, Japan. Subsequently, they found the strain showed a new antibacterial spectrum and a yellow crystalline antibiotic substance was extracted. Two years later, the antibiotic thiolutin (2) was isolated by a research team in Pfizer, from a soil bacterium Streptomyces albus and described as a neutral, optically inactive, yellow-orange substance which appeared to resemble 1 at that time (Figure 1) [6]. Accordingly, the arranged interchange of the substances between the two research groups led to a conclusion that both compounds belong to the same family of antibiotics but are differentiated from their molecular formulas. The empirical formula of C8H8N2O2S2 and C9H10N2O2S2 for 1 and 2, respectively, were proposed in 1952 (Figure 1) [19]. Both substances were of great interest at that time because of their high activity against a variety of fungi, ameboid parasites, Gram-positive, Gram-negative and acid fast bacteria [20].

Figure 1. N-methyl, N-acylpyrrothine derivatives.
Figure 1. N-methyl, N-acylpyrrothine derivatives.
Marinedrugs 11 03970 g001 1024

Further study of UV absorption spectrum and chemical degradation [21] led to the elucidation of the structure of 2 to be an acetamide of 6-amino-4,5-dihydro-4-methyl-5-oxo-1,2-dithiolo[4,3-b]pyrrole. Accordingly, 1 was proposed to be the 3-propionamido derivative of 2, which only differs from the length of acyl moiety in 2 (Figure 1).

Since then, 1 and 2 were repeatedly discovered from various actinomycete strains [22,23]. Isobutanoylpyrrothine(ISP) (3) (Figure 1) was first isolated from Streptomyces pimprina along with 1, 2 and a polyene (heptaene) [8]. More recently, the rare actinomycete strain Saccharothrix algeriensis (NRRL B-24137) isolated from a south Algerian soil sample has been found to produce at least five dithiolopyrrolone antibiotics including 2 and four other derivatives of 2, isobutanoylpyrrothine(ISP) (3), butanoylpyrrothine(BUP) (4), senecioylpyrrothine(SEP) (5) and tigloylpyrrothine(TIP) (6) (Figure 1) [9,10]. 36 contain the same chromophore of pyrrothine but differ from the acyl groups. The same research group also found that addition of organic acids into the semi-synthetic media influenced the yield of these dithiolopyrrolones in S. algeriensis [24]. The production of dithiolopyrrolones depends upon the nature and concentration of the organic acids in the culture medium.

Gram-negative bacteria such as symbiotic bacteria Xenorhabdus [11,25] were also found to produce thiolutin-type of dithiolopyrrolone natural products. In 1991, McInerney and co-workers [11] discovered two new N-methylated dithiolopyrrolone compounds (Figure 1), xenorhabdin 4 (7) and xenorhabidin 5 (8), from the culture broth of Xenorhabdusnematophilus XQ1 (ATCC 39497), along with other three des-N-methylated analogues 12, 13 and 14 (see next section). X. bovienii is the only Xenorhabdus species that was found to produce oxidized xenorxide derivatives, 7a and 8a (Figure 1) [26]. Xenorhabdus are symbiotic enterobacteria associated with insect pathogenic, soil-dwelling nematodes of the families Heterorhabditidae and Steinernematidae [27,28]. It is believed that they are carried monoxenically within the intestine of the infective stage of the nematode. After invading the host insect, the nematodes release a toxin and an inhibitor of the insect immune system, as well as releasing Xenorhabdus and other symbionts. The bacterial symbionts, in turn, provide nutrients to the nematodes and produce antibiotics which inhibit the growth of other microbial flora in the insect cadavers. Intriguingly, Xenorhabdus nematophilus has two growth phases when cultured in the lab but only phase one metabolites, including Xenorhabdins, possess a wide spectrum of antibiotic activity.

2.2. N-Acylpyrrothine (Holomycin Type) Derivatives

Holomycin 9 (Figure 2) is a des-N-methylthiolutin and was first identified in 1961 from the culture broth of a new strain of Streptomyces griseus (NRRL 2764), isolated from a soil sample at Riccino, Italy [12]. Although 9 is closely related to 2, these two compounds differ from the physical and chemical properties, such as melting points, IR spectrum and behavior under paper chromatographic examination. Later on, holomycin and N-propionyl derivative 10 (Figure 2) were isolated from mutant strains of Streptomyces sp. P662 [13] and Streptomyces clavuligerus [29]. Interestingly, the wild types of these two Streptomyces strains are also producers of cephamycin C, a potent β-lactam antibiotic, which is biologically synthesized from aminoadipic acid, cysteine and valine [29,30,31]. The wild type Streptomyces sp. P6621 was found to produce cephamycin C [32] but does not produce 9 and 10. Chemical mutagenesis led to generate the mutant Streptomyces sp. P6621-7N49 that only produces half the amount of cephamycin C with the production of 9 and 10 [32]. It was proposed that the production of 9 and 10 decrease the pool of cysteine available for cephamycin C biosynthesis and thus diminishes the level of cephamycin C produced. Streptomyces clavuligerus ATCC27064 has capacity to produce two clinically important antibiotics, the β-lactam antibiotic cephamycin C [33] and the β-lactamase inhibitor clavulanic acid [34]. Similar to the above case, the production of holomycin 9 in the wild type S. clavuligerus is not detectable. The mutant strain IT1, generated by UV mutagenesis of the parent strain of S. clavuligerus, led to overproduction of holomycin [29]. It was proposed that the unstable genetic element affect the production of holomycin [35]. Holomycin was also found from marine Streptomyces sp. M095 which was isolated from a marine sediment sample of Jiaozhou Bay, China [36].

Figure 2. N-acylpyrrothine derivatives.
Figure 2. N-acylpyrrothine derivatives.
Marinedrugs 11 03970 g002 1024

Gram-negative bacteria were also found to produce holomycin. Recently, the bioassay-guided isolation has led to the rediscovery of holomycin from a marine Gram-negative bacterium Photobacterium halotolerans S2753 collected from the southern Pacific Ocean [37]. Furthermore, the fish pathogen Yersinia ruckeri was also identified to be a holomycin producer, evidenced through genome-mining, chemical isolation and characterization approaches [38].

In 1969, a new dithiolopyrrolone natural product, antibiotic vD844 (11) (Figure 2), was isolated from an unidentified actinomycetes species from a soil sample collected near Copenhagen [14]. Interestingly, antibiotic vD844 has an identical molecular formula and molecular weight to holomycin. Chemical analysis and X-ray finally elaborated that vD844 was 5-oxo-6-(N-methylformamido) 4,5-dihydro-1,2-dithiolo[4,3-b] pyrrole [14].

The symbiotic bacterium Xenorhabdus nematophilus XQ1 ATCC 39497 was also found to produce three holomycin derivatives Xenorhabdin 1 (12), Xenorhabdin 2 (13) and Xenorhabdin 3 (14) (Figure 2) [11]. This is the only example among all of the dithiolopyrrolone bacterial producers that produces both of thiolutin-type and holomycin-type natural products, indicating that the N-methylation may not be tightly regulated in this organism.

2.3. Thiomarinols, PKS/NRPS Hybrid Antibiotic Natural Products

Thiomarinols (Figure 3) are a unique subgroup of dithiolopyrrolone natural products in that they are hybrid potent antibiotics composed of a dithiolopyrrolone moiety attached via an amid linkage with a pseudomonic acid analogue, an esterified unusual fatty acid component connected with the monic acid, an important polyketide moiety of an antimethicillin resistant Staphylococcus aureus (MRSA) antibiotic mupirocin [39,40].

Figure 3. Thiomarinols, hybrid antibiotic natural products.
Figure 3. Thiomarinols, hybrid antibiotic natural products.
Marinedrugs 11 03970 g003 1024

Pseudoalteromonas is a genus of marine Gram-negative bacterium. The pseudoalteromonas species isolated before 1995 were originally part of the alteromonas genus. Psudoalteromondas are known to frequently be bioactive [41] and are often found in association with higher eukaryotes or marine surfaces [42].

In 1993, a Japanese group first reported the fermentation and isolation of thiomarinol A (21) (Figure 3) from a marine Gram-negative bacterium Pseudoalteromonas sp. nov. SANK 73390 isolated from seawater [16]. Its molecular formula was first established to be C30H44N2O9S2 with typical UV maxima (300 and 387 nm in methanol) of dithiolopyrrolone chromophore. Further NMR analysis confirmed that the structure of 21 (Figure 3) is a hybrid of two antibiotics, a pseudomonic acid analogue and holothin [43]. Some pseudomonic acid derivatives were also isolated from a marine bacterium Alteromonas sp. associated with the marine sponge Darwinella rosacea in 1992 [44]. The structure of pseudomonic acid A was identical with that of 21 except for the holothin chromophore moiety in 21. Soon after this, six new analogues, thiomarinols B–G (2027) (Figure 3), were isolated from the same strain [17,18].

Thiomarinol B 20 [17] possesses the same pseudomonic acid component as 21 but differs in the holothin chromophore. The UV spectra and chemical and other spectral properties and X-ray confirmed the presence of a sulfone in the difulfide part of holothin in 26, rendering that 26 is the only sulfone-containing derivative in the thiomarinol family. The holothin and 7-hydroxyoctanoic acid components of 22, 23, 24 and 25 are identical with that of 21 but differ in the modification in the monic acid moiety from 21. 27 was determined to be 4-deoxythiomarinol A [18]. Compound 23 was found to be 14-homothiomarinol A with one extra methyl in the terminal of the monic acid moiety and 25 to be 13-ketothiomarinol A. 27 is a hybrid of 6-deoxypseudomonic acid B and holothin [18]. Compound 24 is the only thiomarinol derivative containing 8-hydroxynonoic acid moiety but other components of holothin and monic acid are identical to 21. More recently, six new xenorhabdin derivatives (1520) (Figure 3) were also found in the culture broth of Pseudoalteromonas SANK73390 with the different chain length of fatty acid component [15].

3. Bioactivities and Possible Mode of Action

Dithiolopyrrolone natural products possess broad spectrum of biological activities (Table 2). As one of the first discovered members, thiolutin (2) has been extensively studied and found that 2 has a wide range of activities against a variety of Gram-positive and Gram-negative bacteria, protozoa, yeast, pathogenic fungi, and even several human cancer cell lines [45,46,47,48,49,50]. The later discovered that 9 showed similar antibacterial profile to thiolutin [13,29]. Although the structural difference between these two compounds only lies on the methyl group on N4, it is interesting to note that 9 appeared to possess no antifungal activity [13,29]. Thiomarinols are a special group of dithiopyrrolones, which are actually hybrid molecules consisting of one pyrrothine and one psedomonic acid moiety varying in length [16,17,18,51]. Owing to the unique mupirocin-like component in the structure, thiomarinols display much higher activity against Staphylococcus aureus, especially the methicillin-resistant S. aureus (MRSA), than other dithiolopyrrolones [15].

Table 2. Biological activities of dithiolopyrrolones.
Table 2. Biological activities of dithiolopyrrolones.
MIC (μg/mL)/IC50 (μM)
G+Bacilius coagulans CIP 6625<0.2NCNC
Bacillus subtilis ATCC 66332NCNC
Microcoecus leteus ATCC 9314<0.2NCNC
Staphylococcus aureus204<0.01
G−Klebsiella pneumonia180.78
Escherichia coli>100<23.13
Salmonella enteric>100NCNC
Pseudomanas aeruginosa>100640.39
Proteus mirabilisNC4NC
Haemophilus influenzaNC<0.3NC
FungiMucor ramannianus NRRL 182910NCNC
Penicillium sp.20NCNC
Alternaria sp.20NCNC
Candida albicans20NCNC
YeastSaccharamyces cerevisiae10NANC

Microbials were tested as MIC and HUVEC were tested as IC50 values. NC, unclear; NA, no activity; HUVECs, human umbilical vein endothelial cell; VTN, vitronectin; FN, fibronectin; COL, collagen type IV.

The mode of action for dithiolopyrrolones has been studied to a great extent using 2/9 as the model compounds [29]. It was established that the antibacterial activity of 2/9 against E. coli is attributed to the inhibition of RNA synthesis [29,52,53]. However, the dispute of whether 2/9 inhibits the initiation or elongation steps of RNA synthesis has been argued for a long time [52,54]. Khachatourians and Tipper measured the effects of 2 on β-galactosidase expression in E. coli, and suggested that this compound inhibits RNA chain elongation [52]. In contrast to this conclusion, the study performed by Sivasubramanian and Jayaraman indicated that 2 inhibits initiation of RNA transcription [54]. To resolve the above discrepancies, the mode of action of dithiolopyrrolones was reinvestigated using holomycin as the model [50]. By characterizing the effects of 9 on the kinetics of β-galactosidase expression, Oliva et al. confirmed that 9 inhibits RNA polymerase at the level of RNA chain elongation rather than initiation [50]. More supportive evidence comes from a study characterizing activities of various RNA polymerase inhibitors against Staphylococcus aureus mutants that display resistance to rifampin, an inhibitor of transcription initiation. O’Neil et al. found that both 2 and 9 are both active against S. aureus strains containing mutant RNA polymerase β-subunit (rpoB) gene that confers resistance to rifampin [55]. This result suggested that the target site(s) of dithiolopyrrolones is different from that of rifampin, and dithiolopyrrolones only affect mRNA transcription at the phase of elongation. Recently, an RNA methyltransferase Hom12, which can methylate the RNA and hence protect the host from the cytotoxic effect of 9, was characterized in the 9 producing fish pathogen Yersinia ruckeri [38]. This study proposed that RNA methylation may interfere with the activity of RNA polymerase by 9, consistent with the finding that the mutant E. coli strain harboring hom12 showed tolerance to 9. Future studies on the exact RNA substrate of Hom12 and the relationship between such RNA species and RNA polymerase will shed light on the in vitro reconstitution of the mode of action of holomycin, and therefore the whole dithiolopyrrolone family.

The mechanism underlying the inhibition of RNA polymerase by dithiolopyrrolones still remains to be revealed. However, the structural characteristics of dithiolopyrrolone core scaffold, the disulfide-bridged heterocycle, may give some hints to this question. The mycotoxin gliotoxin and the histone deacetylase inhibitor FK228 are two compounds that possess a similar disulfide bond [38,56]. It was shown that the activities of these molecules are due to the reduction of the disulfide bond in the cell, giving rise to the more active dithiol groups which can react with target proteins' thiol groups [56,57]. By analogy, dithiolopyrrolone compounds may behave in the same way to inhibit RNA polymerase. In support of this hypothesis, Li et al. found that there were a number of intermediates, with the dithiol groups modified by a combination of mono- and di-S-methylation, accumulating in a mutant holomycin producer, in which the gene (hlmI) responsible for the disulfide formation was deleted [58]. This result suggested that the dithiol intermediates produced by ΔhlmI mutant may be very active even toxic, and the host can protect itself by incapacitating the reactive dithiol groups. Beside the above "reduction" mechanism concerning dithiolopyrrolone action mode, an “oxidation” mechanism was also proposed. Juhl et al. found that E. coli strains carrying the thdA (sulfone oxidase) mutation showed hypersensitivity to thiolutin. Since these thdA mutants possess high oxidation activities toward a wide variety of substrates containing sulfur, the authors implied that oxidation of thiolutin may induce its toxicity in the cell [59].

RNA polymerase represents an attractive target for the development of high-efficiency antibacterial drugs because transcription is essential for bacterial growth and survival [60]. So far, the class of rifamycins is the only clinically used natural RNA polymerase inhibitor [61]. However, with the emergence of rifamycin-resistant bacteria that even possesses cross-resistance to the other RNA polymerase inhibitors, the development of new drug candidates that have different target sites from rifamycins is in demand [60,61]. Dithiolopyrrolone class of compounds, such as 2 and 9, could be considered to be the warhead for designing the next-generation of RNA polymerase-associated drugs. Yakushiji et al. recently developed a series of novel bacterial RNA polymerase inhibitors by incorporating holomycin into several myxopyronin skeletons [57]. One of the resulting compounds exhibits good antimicrobial activity against Gram-positive bacteria, implying that using the pyrrothine as a component to make hybrid-type drugs is a promising direction for novel drugs development.

4. Total Synthesis of Dithiolopyrrolones

Total syntheses of dithiolopyrrolones have been attempted since the early 1960s, and many synthetic strategies have been developed.

The first total synthesis of thiolutin (2) and derivatives was achieved in 1962 starting with N-methyl-1-ethoxycarbony l-2-diethoxyethylamine and methoxycarbonylacetyl chloride [62]. In 1964, Lukas and Buchi proceeded along a different synthetic route with the starting material of S-benzyl-l-cysteine ethyl ester but through the same dithiol intermediate as reported in 1962 (Scheme 1) [63]. These syntheses of 9, however, have relied on the oxidation of the common intermediate, reduced dithiolopyrrolone dithiols, to create the disulfide ring and have not been adaptable to the preparation of ring-substituted derivatives [64]. Later on, Ellis et al. devised the synthesis of the preparation of holomycin and its 3-carboxylated derivative starting with p-methoxyacetophenone and methyl thioglycolate (Scheme 2) [65]. Among these 10-stage synthetic steps, highlighted were the two key reactions, construction the substituted pyrrolinone ring by cyclization of the methoxalylamine and contraction of the 6-membered dithioketal to the 5-membered disulfide ring of 3-carboxyholomycin adapted from the method developed by Kishi and co-workers [66]. Holomycin (9) was finally obtained in a single step by cleavage and concomitant decarboxylation from 3-carboxyholomycin 9a’ (Scheme 2) [65].

Scheme 1. Lukas’s synthesis of holomycin.
Scheme 1. Lukas’s synthesis of holomycin.
Marinedrugs 11 03970 g006 1024

Recently an efficient and convenient synthetic route has been developed for the preparation of 9, xenorhabdin I (12) and some other analogs thereof (Scheme 3) [67]. The reaction started with 1,3-dichloroacetone by treatment of p-methoxybenzylthiol (PMBSH) to yield the 12a in a one-pot procedure. The amine functionality was next introduced by reaction of 12b with ammonium acetate to give 12c in 87% yield. TFA-pyrrothine 12d was generated by refluxing 12c in TFA in the presence of m-cresol in order to remove the PMP protecting groups and simultaneously form the pyrrothine skeleton. The benefit of this synthetic route would give fast access to an intermediate pyrrothine with a free amino, which would ease analog synthesis. Another highlight in this contribution was that this method used p-methoxybenzyl (PMB) group instead of t-butyl group as protective group which requires the use of toxic and environmentally hazardous mercuric acetate for removal (Scheme 3) [67].

Scheme 2. Ellis’s synthesis of holomycin (9) and its carboxylated derivative (9a’).
Scheme 2. Ellis’s synthesis of holomycin (9) and its carboxylated derivative (9a’).
Marinedrugs 11 03970 g007 1024
Scheme 3. Hjelmgaard’s synthesis of holomycin and its derivatives.
Scheme 3. Hjelmgaard’s synthesis of holomycin and its derivatives.
Marinedrugs 11 03970 g008 1024

The downside of the methods presented on Scheme 1, Scheme 2 and Scheme 3 are the relatively low yields and lack of versatility in providing various derivatives needed for biological studies. Stachel and co-workers demonstrated modified and versatile synthetic routes of preparation of ring-fused dithiinopyrroles, dithiolopyrroles and pyrroloisothiazoles [68]. A series of phenyl-substituted dithiolopyrrolones were prepared starting from the known lactam pyrrolinone. The key reaction was based on the nucleophilic displacement of the methoxy and bromine by Na2S, giving a dithiolate; the latter was readily oxidized by O2 in air forming dithiolopyrrolones. Furthermore, the N-methylated derivatives were obtained by reacting with MeI (Scheme 4) [69].

Scheme 4. Stachel’s synthesis of dithiolopyrrolones.
Scheme 4. Stachel’s synthesis of dithiolopyrrolones.
Marinedrugs 11 03970 g009 1024

Li et al. developed an expedient manner (seven steps) of the total synthesis of dithiolopyrrolones from commercially available starting materials in a kilogram scale and prepared 17 of dithiolopyrrolone derivatives with aromatic substituents on the pyrrolone nitrogen atom (Scheme 5) [70,71]. The key step for introduction of N-substituted aromatic group was the reaction of ketone intermediate with the appropriate aromatic primary amines in tetrahydrofuran to afford the cyclic enols in good yield (60%–70%), followed by the conversion into the corresponding cyclic enamines. The remaining steps towards the synthesis of pyrrolones were considerably similar to the ones previously reported [67].

Scheme 5. Li’s synthesis of dithiolopyrrolone derivatives.
Scheme 5. Li’s synthesis of dithiolopyrrolone derivatives.
Marinedrugs 11 03970 g010 1024

Gao and Hall et al. reported the first total synthesis of a thiomarinol derivative with three components, pseudomonic acid, 8-hydroxyoctonoic acid and anhydroornithine [72]. The total yield after 13 synthetic steps was 22%. The concise synthetic route of a stereoconvergent three-component strategy was considered to be amendable to the design of other analogues, i.e., thiomarinol A.

5. Biosynthesis of Dithiolopyrrolones

5.1. Precursor-Directed Biosynthesis (PDB) of Dithiolopyrrolones

The generation of natural product analogues is often important for improving bioavailability to fine tune compounds’ activity [73]. PDB has proven to be a powerful tool for the synthesis of structural analogues [74]. PDB takes advantage of the natural flexibility of biosynthetic pathways toward the acceptance of unnatural precursor analogues. Analogs of biosynthetic building blocks are designed, synthesized and fed to the organism and the biosynthetic enzymes, if in degree of promiscuity, then incorporate this unnatural building block into the natural product so that analogs of natural product of interests will be generated [74].

Saccharothrix algeriensis is a rare actinomycete isolated from the soil of the palm groves of Southern Algeria [9]. Five thiolutin-type dithiolopyrrolones with different branched chains and chain length of acyl groups were obtained from the fermentation broth of S. algeriensis, implying that there may have some degree of plasticity for the enzymes responsible for bioconversion of organic acid into acyl-CoA and installation of acyl-CoA into the holothin skeleton. Bouras et al. then explored this property by introduction of various organic acids into fermentation media. The addition of only three acids, benzoic, valeric and cinnamic acids, led to the production of unnatural dithiolopyrrolones identified in the culture broth of S. algeriensis [24]. Of particular interest was the incorporation of aromatic acids into the scaffolds of dithiolopyrrolones, indicating the enzyme promiscuity in the biosynthetic pathway of dithiolopyrrolones in S. algeriensis (Figure 4). Adding valeric acids into the fermentation medium of S. algeriensis also induced the production of three new antibiotic dithiolopyrrolones, formylpyrrothine 28, valerylpyrrothine 29 and isovalerylpyrrothine 30 [75]. Further exploitation of PDB method led to identification of four new dithiolopyrrolone antibiotics, crotonylpyrrothine 31, sorbylpyrrothine 32, 2-hexenylpyrrothine 33 and 2-methyl-3-pentenylpyrrothine 34, in the presence of 5 mM sorbic acid in the production medium, showing the remarkable flexibility of the dithiolopyrrolone biosynthetic pathway in S. algeriensis [76].

Recent genome sequencing of the thiomarinol producer bacterium Pseudoalteromonas sp. SANK 73390 indicated that thiomarinols are biosynthesized from two independent pathways, an AT-less type I PKS one for marinolic acid and a NRPS one for holothin [77]. Inactivation of one of domains in PKS genes resulted in the PKS mutant in which the production of thiomarinols was completely abolished. Feeding pseudomonic acid A (0.1 mg mL−1) immediately after inoculation resulted in identification and isolation of two new derivatives, a pyrrothine derivative of pseudomonic acid 35 and its 4-hydroxylated analogue 36 along with three derivatives of pseudomonic acid A (Figure 4) [15].

Figure 4. “Unnatural” dithiolopyrrolone natural products using precursor-directed biosynthesis.
Figure 4. “Unnatural” dithiolopyrrolone natural products using precursor-directed biosynthesis.
Marinedrugs 11 03970 g004 1024

5.2. Biosynthesis of Dithiolopyrrolones

Despite the emerging importance of dithiolopyrrolones, the dearth of the biosynthetic knowledge was particularly striking until recently. The difficulty to locate constituent gene segments even if they were clustered may result from the unusual heterobicyclic and highly oxidative dithiolopyrrolone skeleton. Early feeding experiment demonstrated that l-cystine appeared to be the precursor of dithiolopyrrolone biosynthesis and that pyrrothine seemed to be an intermediate in the pathway from l-cystine to dithiolopyrrolone [78,79].

It has been speculated that an N-acetyltransferase type of enzyme could be involved in the late stage of the holomycin biosynthesis. Indeed, the presence of such an enzyme appeared to be necessary for the amide bond formation between the holothin nucleus (deacetylholomycin) and acetylCoA in cell-free extracts of the holomycin-overproducing mutants of S. clavuligerus [80]. A similar result was also shown that incubation with N-methylpyrrothine and acetylCoA or benzoylCoA in the cell-free extract of S. algeriensis NRRL-24137 resulted in formation of thiolutin or N-methyl-N-benzoylpyrrothin, respectively [81].

5.2.1. Identification of the Holomycin Gene Cluster in S. clavuligerus

Analysis of Streptomyces clavuligerus genome sequence indicated that S. clavuligerus has a relatively small chromosome of 6.8 Mb in length but contains a megaplasmid of 1.8 Mb in length [82]. There are 48 putative secondary metabolite gene clusters that have been identified by a homolog comparison. Among these gene clusters, 23 are in the chromosome and 25 are in the megaplasmid. Taken advantage of the genome mining strategy, the holomycin biosynthetic gene cluster in S. clavuligerus has recently been identified and characterized, as evidenced through heterologuous protein expression, enzyme activity assays [83] and heterologuous expression of the gene cluster [84,85].

The holomycin gene cluster consists of 12 genes, spanning an approximately 17.6 kb region in the chromosome of S. clavuligerus, ten of which the functions have been assigned (Figure 5, Table 3) [83,84]. The gene cluster only contains a gene (orf3488 [83] and homE [84]) encoding a multidomain non-ribosomal peptide synthetase (NPRS) with a conical order of cyclization (Cy), adenylation (A) and thiolation domains (T). Of particle interest is that the gene cluster also encodes four flavin-dependent oxidoreductases (ORF3483, 3487, 3489, 3492 [83] or HomB, D, F, I [86]) and a putative acetyltransferase (ORF 3484 [83] or HomA [84]). Additionally, three stand-alone NRPS encoded proteins were found in the gene cluster. These are freestanding C domain (ORF3495 [83] or HomK [84]), the Te Domains (ORFs 3486 and 3494 [83] and HomC and HomJ [84]). Two genes in the cluster, orf 3491 and 3496 (homH and homL [84]), respectively, were predicted to be a regulatory gene and transporter gene, respectively.

Figure 5. Comparison of the genetic organization of the holomycin biosynthetic gene clusters from S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
Figure 5. Comparison of the genetic organization of the holomycin biosynthetic gene clusters from S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
Marinedrugs 11 03970 g005 1024
Table 3. Deduced functions of open reading frames (ORFs) that were predicted to be involved in the biosynthesis of holomycin in S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
Table 3. Deduced functions of open reading frames (ORFs) that were predicted to be involved in the biosynthesis of holomycin in S. clavuligerus, Y. ruckeri and Pseudoalteromonas, respectively.
ORFs in S. clavuligerus [83]Homolog in Y. ruckeri (Identity %) [38]Homolog in Pseudoalteromonas (Identity %) [87]Proposed Function
ORF3489(HlmF)Hom1 (61%)HolG (72%)PPC-DC decarboxylase
ORF3490(HlmG)Hom2(65%)HolF (70%)Globin
ORF3483(HlmA)Hom3 (38%)HolE (45%)N-acyltransferase
ORF3485(HlmB)Hom4 (58%)HolD (63%)Acyl-CoA dehydrogenase
ORF3486(HlmC)Hom5 (36%)HolC (42%)Thioesterase
ORF3487(HlmD)Hom6 (47%)HolB (59%)FMN-dependent oxdioreductase
ORF3488(HlmE)Hom7 (47%)HolA (55%)NRPS (Cy-A-T)
ORF3491(HlmH)Hom8 (61%)MFS efflux protein

Gene disruption of orfs 3488 and 3489 in the holomycin-overproducing mutant completely abolished holomycin production, indicating that the identified gene cluster is responsible for holomycin production [83]. We also demonstrated that introduction of the whole gene cluster into a heterologuous host Streptomyces albus resulted in the production of holomycin in the mutant S. albus [84].

5.2.2. Characterization of Key Enzymes during the Holomycin Biosynthesis in S. clavuligerus

Given that genetic evidence demonstrated the involvement of ORF3488 for the holomycin production, it was overproduced in E. coli. The amino acid-dependent exchange assay showed that the adenylation domain of ORF3488 proceeds aminoacylation of l-cysteine but not the other proteinogenic amino acid with a Km value of 1 mM and a Kcat value of 98 min−1 [83].

The predicated activity of the encoded ORF3483 was an N-acetylCoA transferase. Incubation of recombinant ORF3483 (10 nM) with acetylCoA and holothin (20 nM) showed the formation of holomycin with an apparent Km of 6 nM and a Kcat of 80 min−1, reassuring the involvement of ORF3483 during the biosynthesis of holomycin (Scheme 6). Surprisingly, recombinant ORF3483 was also able to utilize longer chain acyl CoAs (hexanoyl, octanoyl and palmitoylCoA) as substrates with less efficiency. The apparent Km of 30 nM and apparent kcat of 0.07 min−1 was obtained from octanoylCoA in the presence of 20 nM holothin [83]. Longer chained acyl holothins were not observed in the fermentation broth of S. clavuligerus presumably because the pools of these fatty acids or acylCoAs could be very low. Identification of longer acyl chain variants of dithiolopyrrolones, however, was observed in other microorganisms [9,16].

Scheme 6. Biochemical study confirmed that the N-acetyl-CoA transferase ORF3483 is responsible for the amid bond formation at the late stage of the holomycin biosynthesis in Streptomyces clavuligerus.
Scheme 6. Biochemical study confirmed that the N-acetyl-CoA transferase ORF3483 is responsible for the amid bond formation at the late stage of the holomycin biosynthesis in Streptomyces clavuligerus.
Marinedrugs 11 03970 g011 1024

It is rare for molecular scaffolds of bacterial natural products to contain disulfide bonds, and the mechanism of disulfide bond formation in these products is poorly understood until recently [86]. The first evidence of the disulfide bond formation was reported in 2009 during the study of the biosynthesis of FK228, a disulfide-containing anticancer despeptide natural product isolated from the soil bacterium, Chromobacterium violaceum 968. The identified enzyme DepH represents a new subclass of the thioredoxin protein superfamily [86]. In 2010, another homolog enzyme GliT was found to be responsible for the disulfide-bond formation in the biosynthesis of Gliotoxin, a disulfide-containing metabolite isolated from the human pathogen Aspergillus fumigatus [88]. Although both DepH and GliT belong to a new member of FAD-dependent dithiol oxidases, DepH utilizes NADP+ as the electron acceptor [86] while GliT use O2 to promote the disulfide formation [88].

In silica analysis of the holomycin gene cluster in S. clavuligerus showed that the encoded flavoenzyme HlmI [89] (ORF3492 [83] and HomI [84]) may function analogously to DepH or GliT to convert dithiol form of reduced holomycin 9b’/holothin 9b into holomycin 9/holothin 9a (Scheme 7). Indeed, incubation of purified recombinant HlmI (50 nM) with FADH2 and reduced holomycin 9b’ (5–100 nM) led to the rapid formation of holomycin in presence of oxygen with an apparent Km of 4.6 ± 1.9 nM and an apparent kcat of 333 ± 28 min−1. Although HlmI clearly accelerated the disulfide bond formation from reduced holothin 9b to holothin 9a, the nonenzymatic oxidation in presence of oxygen precluded kinetic measurement [89]. It was concluded that HlmI is a GliT-like FAD-dependent dithiol oxidase, using O2 as the oxidative agent for the formation of intramolecular disulfide bridges in the late stage of the holomycin biosynthesis [89].

Scheme 7. Biochemical study confirmed that the dithiol oxidase HlmI is responsible for the disulfide bond formation using molecular oxygen as a cofactor.
Scheme 7. Biochemical study confirmed that the dithiol oxidase HlmI is responsible for the disulfide bond formation using molecular oxygen as a cofactor.
Marinedrugs 11 03970 g012 1024

5.2.3. Regulation of the Biosynthesis of Holomycin in S. clavuligerus

Regulation of the holomycin production in Streptomyces appeared to be very complex. Early studies indicated that holomycin production appeared to be associated with the production of cephamycin C. For example, the wild type Streptomyces sp. P6621 produces cephamycin C but does not produce 9. Chemical mutagenesis of Streptomyces sp. P6621 resulted in the production of 9 and the reduced yield of cephamycin C [32]. The wild type S. clavuligerus only produces trace amount of holomycin. UV mutagenesis led to generate the mutant IT1 that was a holomycin-overproducing strain [29]. In 2001, Liras et al. demonstrated that gene knockout in the gene cluster of clavulanic acid in S. clavuligerus resulted in overproduction of holomycin, suggesting that the intriguingly intricate cross-regulation between the biosynthetic pathways of clavulanic acid and holomycin [80].

A rhodanese-like protein was found to be highly overrepresented in the proteome of the holomycin-overproducing mutant of Streptomyces clavuligerus. Disruption of the rhodanese-like gene resulted in great loss of holomycin production in the rhlA mutants [90].

Addition of arginine appears to stimulate the production of holomycin [91,92]. The gene argR is a universally conserved repressor gene in the arginine biosynthesis in S. clavuligerus NP1. Disruption of argR resulted in holomycin-overproducing mutant, S. clavuligerus CZ [93]. Comparative proteomic studies demonstrated that the expression levels of proteins involved in acetyl-CoA and cysteine biosynthesis increased in the mutant CZR strain, consistent with the holomycin overproduction phenotype [93].

The genes afsR and afsS in S. clavuligerus ATCC27064 encode proteins resembling the well-known antibiotic biosynthetic activators. It was found that re-introduction of afsRScla genes into the wild-type S. clavuligerus activated the normally silent holomycin biosynthetic gene cluster while the production of clavulanic acid was also increased 5-fold in resultant mutant compared to the wild-type strain [94].

A competition-based adaptive laboratory evolution could accelerate the discovery of antibiotics when an antibiotic-producing microorganism is competed against a drug-resistant pathogen [95]. Of particular interest is that actinomycetes that are well known producer of secondary metabolites could adaptively evolved in the laboratory to produce new antibacterial compounds, of which the production is silent in the normal laboratory culture conditions [96]. Palsson et al. demonstrated that, after several rounds of co-culturing S. clavuligerus and the methicillin-resistant Staphylococcus aureus (MRSA) N315, a mutant strain of S. clavuligerus emerged that acquired the ability to constitutively produced holomycin, the antibacterial agent that inhibits the growth of MRSA [97]. Genome sequencing revealed that the mutant strain had lost the megaplasmid, and acquired genetic mutations that affected secondary metabolite biosynthesis [97].

More recently, RT-PCR transcription analysis of the holomycin-overproducing mutant of S. clavuligerus showed a higher transcription of some genes in the holomycin gene cluster compared with the ones in the wild-type strain [85]. This result was consistent with the proteomic analysis of the holomycin overproducer mutant that some transcribed proteins related to the holomycin pathway were overexpressed [85].

5.2.4. Identification of the Holomycin Gene Cluster in the Fish Pathogen Yersinia ruckeri

Homolog search indicated that several open reading frames (ORFs) in the genome of the fish pathogen Yersinia ruckeri appear to be homologous to the ones in the holomycin pathway of S. clavuligerus, including three oxidoreductases, one thioesterase and, more importantly, one multidomain NRPS with a conical order of Cy-A-T arrangement. However, this gene cluster lacks two key homolog genes, one encoding the dithiol oxidase that promotes the disulfide bridge formation and the other encoding the freestanding condensation domain. Our chemical isolation and structural elucidation demonstrated that Y. ruckeri is a producer of holomycin. Gene disruption of hom6, a homolog of homD [84], completely abolished the production of holomycin in the mutant strain, suggesting that the identified gene cluster directs the biosynthesis of holomycin.

5.2.5. The Proposed Mechanism of the Formation of Holomycin

Despite the differences between two holomycin gene clusters from the Gram-positive bacterium S. clavuligerus and the Gram-negative bacterium Y. ruckeri, the underlying chemical logic of holomycin formation should be similar (Scheme 8).

Biochemical and genetic evidence demonstrated that the formation of holomycin should follow the same chemical logic as other biosynthetic pathways of non-ribosomal peptides in which a tridomain non-ribosomal peptide synthetase (HomE [84] or HlmE [83] or Hom7 [38]) first selects and activates l-cysteine. The condensation activity was proposed to follow an unusual pathway [98]. In S. clavuligerus, it was proposed that the flavin-dependent acyl-CoA dehydrogenase (HomB [84] or HlmB [83]), the standalone C domain and the Cy domain of the NRPS are responsible for oxidizing, coupling, and cyclizing two cysteine residues to yield a cyclodithiol-PCP-domain tethered intermediate 9f. In Y. ruckeri, no dedicated C domain can be found within the holomycin gene cluster. Thus the Cy domain may have dual functions that catalyze both condensation and cyclization of C-C formation, although it clearly remains speculative until the studies of the detailed mechanism is carried out [38].

Scheme 8. Proposed biosynthetic pathway of holomycin.
Scheme 8. Proposed biosynthetic pathway of holomycin.
Marinedrugs 11 03970 g013 1024

The cyclodithiol-PCP-domain tethered intermediate 9f could then be hydrolyzed by the thioesterase (HomC [84] or HlmC [83] or Hom5 [38]) to generate the free acid intermediate 9e. The glucose-methanol-choline oxidoreductase homolog (HomD [84] or HlmD [83] or Hom6 [38]) could be responsible for the 2-electron oxidation step on 9d into 9c. HomF [84] (HlmF [83] or Hom1 [38]) is an analog of phosphopantothenoylcystein decarboxylase in coenzyme A biosynthesis. In the reaction cycle of PPC-DC, the thiol moiety of pantothenoylcysteine is first oxidized and spontaneously decarboxylatedto generate the pantothenoylaminoethenethiol intermediate, which is finally reduced to form pantothenoylcysteamine. In analogy, HomF [84] (HlmF [83] or Hom1 [38]) could catalyze the decarboxylation of the intermediate 9c into 9b. The assignment does not, however, suggest a preferred sequence for these activities [83]. In S. clavuligerus, HlmI appeared to play important roles in the biosynthesis of holomycin. Li et al. has confirmed that recombinant HlmI mediates the disulfide bond formation from reduced holomycin 9a to holomycin 9 using O2 as cofactor, and it was proposed that HlmI is involved in the late stages of holomycin biosynthesis [89]. Gene disruption of hlmI resulted in decreased production of holomycin and increased sensitivity toward holomycin [89]. The homolog of HlmI, however, cannot be found in the holomycin gene cluster in Y. ruckeri and a similar absence was also observed in the thiomarinol gene cluster from Pseudoalteromonas sp. SANK73390, indicating the different underlying chemical logic of disulfide bond formation in Gram-negative bacteria [38]. Biochemical evidence demonstrated that HlmA is responsible for the acylation of the amino group in holothin 9b or reduced holothin 9a [83].

5.3. Biosynthesis of Thiomarinol Natural Products

Thiomarinols belong to a special group of dithiolopyrrolones in that they are hybrid antibacterial compounds consisting of three components, a pseudomonic acid moiety esterified by a terminal-hydroxy fatty acid (n = 7 or 9) attached to the holothin moiety via an amide linkage.

Recently genome sequence of the thiomarinol-producer bacterium revealed a novel plasmid, pTML1 with the length of 97 kbp [87]. Interestingly, the plasmid contains two distinct gene clusters, one responsible for the biosynthesis of pseudomonic acid and the other for the holothin moiety. The pseudomonic acid gene cluster contains the typical feature of trans-AT/AT-less polyketide synthase (PKS) assembly line in that the encoded multidomain PKSs do not contain dedicated acyltransferase domain to activate the acyl substrate. The gene cluster for holothin moiety is similar to the one in Y. ruckeri, consisting of 7 genes encoding a multidomain NRPS HolA (Cy-A-T, homolog to Hom7), an oxidoreductase HolB (homolog to Hom6), a thioesterase HolC (homolog to Hom5), a dehydrogenase HolD (homolog to Hom4), a N-acyltrasferase HolE (homolog to Hom3), an flavin-dependent oxygenase HolF (homolog to Hom2) and a decarboxylase HolG (homolog to Hom1), respectively (Figure 5). It appeared that the chemical logic for holothin scaffold during the biosynthesis of thiomarinols should be the same as the one of holomycin. Inactivation of holA resulted in completely loss of thiomarinol but the only production of marinolic acid in the mutant strain [77], confirming that the hol gene cluster is responsible for the holothin biosynthesis, and marinolic acids and dithiolopyrrolones are biosynthesized from two independent pathways.

In the late stage of the holomycin biosynthesis from both S. clavuligerus and Y. ruckeri, acyl-CoA was proposed to be the substrate of the acyl CoA transferase that mediates the amide bond formation for the holomycin production. In the thiomarinol biosynthesis, TmlU was assigned as an ATP-dependent ligase, a homolog of SimL in the simocylinone biosynthesis [77,99] and NovL in the novobiocin biosynthesis that catalyze the amide bond forming activity with a variety of carboxylic acids [100]. Inactivation of tmlU completely abolished the production of thiomarinols but resulted in the production of xenorhabdins and marinolic acids, pseudomonic acid derivatives, thus suggesting its role of linking the pseudomonic acid and holothin to generate thiomarinols. The production of xenorhabdins and derivatives, however, indicates that HolE, a homolog of acylCoA transferase, could be the second copy of amide-formation enzyme responsible for the installation of acylCoA into the amino group of holothin to generate xenorhabdins 1420 (Scheme 9).

Scheme 9. Proposed biosynthetic pathway of thiomarinol A.
Scheme 9. Proposed biosynthetic pathway of thiomarinol A.
Marinedrugs 11 03970 g014 1024

6. Conclusions

The family of dithiolopyrrolone natural products has attracted attention from the research communities of natural product chemistry/biosynthesis, synthesis and microbiology on their unique chemical identity and multiple biological activities. There have been challenging questions of the biosynthesis, the complex regulation network and the mode of action of this novel class of molecules during the last decade. Recent efforts on the biosynthetic pathways of holomycin and thiomarinols have just started to uncover the intriguing aspects of the underlying chemical logic, regulation and resistance of this class of molecules. This review article has covered the natural product discovery, synthesis, bioactivity and biosynthesis of this class of natural products in the first time over sixty years. Further progress in this class of molecules will be to understand the biochemistry of the formation of the pyrrolone chromophore and the timing of N-methylation in thiolutin-type of molecules, and to ascertain the exact antibacterial mode of action, which will facilitate a greater understanding of this promising class of antibacterial and antitumor agents.


HD thanks the financial supports from the School of Natural and Computing Sciences, University of Aberdeen. YY thanks the financial supports from “973” Program (2012CB721006) and National Natural Science Foundation of China (81102357).

Conflict of Interest

The authors declare no conflict of interest.


  1. Walsh, C.T.; Wright, G.D. Antimicrobials. Curr. Opin. Microbiol. 2009, 12, 473–475. [Google Scholar] [CrossRef]
  2. Fischbach, M.A.; Walsh, C.T. Antibiotics for emerging pathogens. Science 2009, 325, 1089–1093. [Google Scholar] [CrossRef]
  3. Li, J.W.H.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325, 161–165. [Google Scholar] [CrossRef]
  4. Jiang, C.; Muller, W.E.G.; Schroder, H.C.; Guo, Y. Disulfide- and multisulfide-containing metabolites from marine organisms. Chem. Rev. 2012, 112, 2179–2207. [Google Scholar] [CrossRef]
  5. Umezawa, H.; Maeda, K.; Kosaka, H. Isolation of a new antibiotic substance, aureothricin from a strain of streptomyces. Jpn. Med. J. 1948, 1, 512–517. [Google Scholar]
  6. Tanner, F.W.; Means, J.A.; Davisson, J.W.; English, A.R. Thiolutin, an Antibiotic Produced by Certain Strains of Streptomyces albus. In Proceedings of the 118th Meeting of the American Chemical Society, Chicago, IL, USA, 1950.
  7. Chen, G.; Li, B.; Li, J.; Webster, J. Dithiolopyrrolone derivatives useful in the treatment of prolifeative disease. Patent WO03080624, 2 October 2003. [Google Scholar]
  8. Bhate, D.S.; Hulyalkar, R.K.; Menon, S.K. Isolation of iso-butyropyrrothine along with thiolutin and aureothricin from a Streptomyces sp. Experientia 1960, 16, 504–505. [Google Scholar]
  9. Lamari, L.; Zitouni, A.; Boudjelli, H.; Badji, H.; Sabaou, N.; Lebrihi, A.; Lefebvre, G.; Seguin, E.; Tillequin, F. New dithiolopyrrolone antibiotics from Saccharothrix sp. SA 233. I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. 2002, 55, 696–701. [Google Scholar] [CrossRef]
  10. Lamari, L.; Zitouni, A.; Dob, T.; Sabaou, N.; Lebrihi, A.; Germain, P; Seguin, E.; Tillequin, F. New dithiolopyrrolone antibiotics from Saccharothrix sp. SA 233. II. Physicochemical properties and structure elucidation. J. Antibiot. 2002, 55, 702–706. [Google Scholar] [CrossRef]
  11. McInerney, B.V.; Gregson, R.P.; Lacey, M.J.; Akhurst, R.J.; Lyons, G.R.; Rhodes, S.H.; Smith, D.R.; Engelhardt, L.M.; White, A.H. Biologically active metabolites from Xenorhabdus spp., part 1. Dithiolopyrrolone derivatives with antibiotic activity. J. Nat. Prod. 1991, 54, 774–784. [Google Scholar] [CrossRef]
  12. Gaeumann, E.; Prelog, V. Holothin and derivatives thereof. U.S. Patent 3,014,922 A, 16 December 1961. [Google Scholar]
  13. Okamura, K.; Soga, K.; Shimauchi, Y.; Ishikura, T. Holomycin and N-propionyl-holothin, antibiotics produced by a cephamycin C producer. J. Antibiot. 1977, 30, 334–336. [Google Scholar] [CrossRef]
  14. Von Daehne, W.; Godtfredsen, W.O.; Tybring, L.; Schaumburg, K. New antibiotics containing the 1,2-dithiolo[4,3-b] pyrrole ring system. J. Antibiot. 1969, 22, 233–236. [Google Scholar] [CrossRef]
  15. Murphy, A.C.; Fukuda, D.; Song, Z.; Hothersall, J.; Cox, R.J.; Willis, C.L.; Thomas, C.M.; Simpson, T.J. Engineered thiomarinol antibiotics active against MRSA are generated by mutagenesis and mutasynthesis of Pseudoalteromonas SANK73390. Angew. Chem. Int. Ed. 2011, 50, 3271–3274. [Google Scholar] [CrossRef]
  16. Shiozawa, H.; Kagasaki, T.; Haruyama, H.; Domon, H.; Utsui, Y.; Kodama, K.; Takahashi, S. Thiomarinol, a new hybrid antimicrobial antibiotic produced by a marine bacterium: Fermentation, isolation, structure, and antimicrobial activity. J. Antibiot. 1993, 46, 1834–1842. [Google Scholar] [CrossRef]
  17. Shiozawa, H.; Kagasaki, T.; Torikata, A.; Tanka, N.; Fujimoto, K.; Hata, T.; Furukawa, Y.; Takahashi, S. Thiomarinol B and C, new antimicrobial antibiotics produced by a marine bacterium. J. Antibiot. 1995, 48, 907–909. [Google Scholar] [CrossRef]
  18. Shiozawa, H.; Shimada, A.; Takahashi, S. Thiomarinol D, E, F and G, new hybrid antimicrobial antibiotic produced by a marine bacterium: fermentation, isolation, structure and antimicrobial activity. J. Antibiot. 1997, 50, 449–452. [Google Scholar] [CrossRef]
  19. Celmer, W.D.; Tanner, M.H., Jr.; Lees, T.M.; Solomons, I.A. Characterization of the antibiotic thiolutin and its relationship with aureothricin. J. Am. Chem. Soc. 1952, 74, 6304–6305. [Google Scholar]
  20. Seneca, H.; Kane, J.H.; Rockenbach, J. Bactericidal, protozoicidal and fungicidal properties of thiolutin. Antibiot. Chemother. 1952, 2, 357. [Google Scholar]
  21. Celmer, W.D.; Solomons, I.A. The structures of thiolutin and aureothricin, antibiotics containing a unique pyrrolinodithiole nucleus. J. Am. Chem. Soc. 1955, 77, 2861–2865. [Google Scholar] [CrossRef]
  22. Ninomiya, Y.T.; Yamada, Y.; Shirai, H.; Onistsuka, M.; Suhara, Y.; Maruyama, H.B. Biochemically Active Substances from Microorganisms. V. Pyrrothines, Potent Platelet Aggregation Inhibitors of Microbial Origin. Chem. Pharm. Bull. 1980, 28, 3157–3162. [Google Scholar] [CrossRef]
  23. Miyamoto, N.; Fukuoka, D.; Utimoto, K.; Nozaki, H. The reaction of styryl sulfoxides or sulfones with boranes. Bull. Chem. Soc. Jpn. 1974, 47, 503. [Google Scholar] [CrossRef]
  24. Bouras, N.; Mathieu, F.; Sabaou, N.; Lebrihi, A. Influence on dithiolopyrrolone antibiotic production by organic acids in Saccharothrix algeriensis NRRL B-24137. Process Biochem. 2007, 42, 925–933. [Google Scholar] [CrossRef]
  25. Paik, S.; Park, Y.H.; Suh, S.I.; Kim, H.S.; Lee, I.S.; Park, M.K.; Lee, C.S.; Park, S.H. Unusual cytotoxic phenethylamides from Xenorhabdus nematophilus. Bull. Korean Chem. Soc. 2001, 22, 372–374. [Google Scholar]
  26. Alexander, O.B. Isolation and identification of natural products and biosynthetic pathways from Photorhabdus and Xenorhabdus. Ph.D. Thesis, Saarland University, Saarbrücken, Germany, 18 December 2009. [Google Scholar]
  27. Akhurst, R.J. Taxonomic study of Xenorhabdus, a genus of bacteria symbiotically associated with insect pathogenic nematodes. Int. J. Syst. Bacteriol. 1983, 33, 38–45. [Google Scholar] [CrossRef]
  28. Thomas, G.M.; Poinar, G.O. Xenorhabdus gen. nov., a genus of entomopathogenic nematophilic bacteria of the family Entero-bacteriaceae. Int. J. Syst. Bacteriol. 1979, 29, 352–360. [Google Scholar] [CrossRef]
  29. Kenig, M.; Reading, C. Holomycin and an antibiotic (MM 19290) related to tunicamycin, metabolites of Streptomyces clavuligerus. J. Antibiot. 1979, 32, 549–554. [Google Scholar] [CrossRef]
  30. Trown, P.W.; Abraham, E.P.; Newton, G.G.F. Incorporation of acetate into cephalosporin C. Biochem. J. 1962, 84, 157–161. [Google Scholar]
  31. Trown, P.W.; Smith, B.; Abraham, E.P. Biosynthesis of cephalosporin C from amino acids. Biochem. J. 1963, 86, 284–291. [Google Scholar]
  32. Mamoru, A.; Yashuhiro, I.; Masaki, N.; Hisashi, K.; Shinichi, S. Process for the production of antibiotic substance cephemimycin. Patent US3865693, 11 February 1975. [Google Scholar]
  33. Miller, A.K.; Celozzi, E.; Kong, Y.; Pelak, B.A.; Kropp, H.; Stapley, E.O.; Hendlin, D. Cephamycins, a new family of β-lactam antibiotics. IV. In vivo studies. Antimicrob. Agents Chemother. 1972, 2, 287–290. [Google Scholar] [CrossRef]
  34. Neu, H.C.; Fu, K.P. Clavulanic acid, a novel inhibitor of β-lactamases. Antimicrob. Agents Chemother. 1978, 14, 650–655. [Google Scholar] [CrossRef]
  35. Kirby, R. An unstable genetic element affecting the production of the antibiotic holomycin by Streptomyces clavuligerus. FEMS Microbiol. Lett. 1978, 3, 283–286. [Google Scholar] [CrossRef]
  36. Hou, Y.H.; Li, F.C.; Wang, S.J.; Wang, Q.F. Intergeneric conjugation in holomycin-producing marine Streptomyces sp. strain M095. Microbiol. Res. 2008, 163, 96–104. [Google Scholar] [CrossRef]
  37. Wietz, M.; Mansson, M.; Gotfredsen, C.H.; Larsen, T.O.; Gram, L. Antibacterial compounds from marine Vibrionaceae isolated on a global expedition. Mar. Drugs 2010, 8, 2946–2960. [Google Scholar] [CrossRef]
  38. Qin, Z.; Baker, A.T.; Raab, A.; Huang, S.; Wang, T.H.; Yu, Y.; Jaspars, M.; Secombes, C.J.; Deng, H. The fish pathogen Yersinia ruckeri produces holomycin and uses an RNA methyltransferase for self-resistance. J. Biol. Chem. 2013, 288, 14688–14697. [Google Scholar]
  39. El-Sayed, A.K.; Hotherall, J.; Cooper, S.M.; Stephens, E.; Simpson, T.J.; Thomas, C.M. Characterization of the mupirocin biosynthesis gene cluster from Pseudomonas fluorescens NCIMB 10586. Chem. Biol. 2003, 10, 419–430. [Google Scholar] [CrossRef]
  40. Thomas, C.M.; Hotherall, J.; Willis, C.L.; Simpson, T.J. Resistance and synthesis of the antibiotic mupirocin. Nat. Rev. Microbiol. 2010, 8, 281–289. [Google Scholar] [CrossRef]
  41. Bowman, J.P. Bioactive compound synthetic capacity and ecological significance of marine bacterial genus Pseudoalteromonas. Mar. Drugs 2007, 5, 220–241. [Google Scholar] [CrossRef]
  42. Holmström, C.; Kjelleberg, S. Marine Pseudoalteromonas species are associated with higher organisms and produce biologically active extracellular agents. FEMS Microbiol. Ecol. 1999, 30, 285–293. [Google Scholar] [CrossRef]
  43. Shiozawa, H.; Takahashi, S. Configurational studies on thiomarinol studies. J. Antibiot. 1994, 47, 851–853. [Google Scholar] [CrossRef]
  44. Stierle, D.B.; Stierle, A.A. Pseudomonic acid derivatives from a marine bacterium. Experientia 1992, 48, 1165–1169. [Google Scholar] [CrossRef]
  45. Jimenez, A.; Tipper, D.J.; Davies, J. Mode of Action of Thiolutin, an inhibitor of macromolecular synthesis in Saccharomyces cerevisia. Antimicrob. Agents Chemother. 1973, 3, 729–738. [Google Scholar] [CrossRef]
  46. Tipper, D.J. Inhibition of Yeast Ribonucleic-Acid Polymerases by Thiolutin. J. Bacteriol. 1973, 116, 245–256. [Google Scholar]
  47. Jia, Y.F.; Wu, S.L.; Isenberg, J.S.; Dai, S.J.; Sipes, J.M.; Field, L.; Zeng, B.X.; Bandle, R.W.; Ridnour, L.A.; Wink, D.A.; Ramchandran, R.; Karger, B.L.; Roberts, D.D. Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton. Cell Stress Chaperon 2010, 15, 165–181. [Google Scholar] [CrossRef]
  48. Deb, P.R.; Dutta, B.K. Activity of thiolutin against certain soil borne plant-pathogens. Curr. Sci. India 1984, 53, 659–660. [Google Scholar]
  49. Dai, S.; Jia, Y.; Wu, S.-L.; Isenberg, J.S.; Ridnour, L.A.; Bandle, R.W.; Wink, D.A.; Roberts, D.D.; Karger, B.L. Comprehensive characterization of heat shock protein 27 phosphorylation in human endothelial cells stimulated by the microbial dithiole thiolutin. J. Proteome Res. 2008, 7, 4384–4395. [Google Scholar] [CrossRef]
  50. Oliva, B.; O’Neill, A.; Wilson, J.M.; O’Hanlon, P.J.; Chopra, I. Antimicrobial properties and mode of action of the pyrrothine holomycin. Antimicrob. Agents Chemother. 2001, 45, 532–5329. [Google Scholar] [CrossRef]
  51. Shiozawa, H.; Fukuoka, T.; Fujimoto, K.; Kodama, K. Thiomarinols: Discovery from a marine bacterium, structure-activity relationship, and efficacy as topical antibacterial agents. Annu. Rep. Sankyo. Res. Lab. 1999, 51, 45–72. [Google Scholar]
  52. Khachatourians, G.G.; Tipper, D.J. Inhibition of messenger ribonucleic acid synthesis in Escherichia coli by thiolutin. J. Bacteriol. 1974, 119, 795–804. [Google Scholar]
  53. Khachatourians, G.G.; Tipper, D.J. In vivo effect of thiolutin on cell growth and macromolecular synthesis in Escherichia coli. Antimicrob. Agents Chemother. 1974, 6, 304–310. [Google Scholar] [CrossRef]
  54. Sivasubramanian, N.; Jayaraman, R. Thiolutin resistant mutants of Escherichia coli are the RNA chain initiation mutants? Mol. Gen. Genet. 1976, 145, 89–96. [Google Scholar] [CrossRef]
  55. O’Neill, A.; Oliva, B.; Storey, C.; Hoyle, A.; Fishwick, C.; Chopra, I. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 2000, 44, 3163–3166. [Google Scholar] [CrossRef]
  56. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, N.; Nakajima, I.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002, 62, 4916–4921. [Google Scholar]
  57. Yakushiji, F.; Miyamoto, Y.; Kunoh, Y.; Okamoto, R.; Nakaminami, H.; Yamazaki, Y.; Noguchi, N.; Hayashi, Y. Novel hybrid-type antimicrobial agents targeting the switch region of bacterial RNA polymerase. ACS Med. Chem. Lett. 2013, 4, 220–224. [Google Scholar] [CrossRef]
  58. Li, B.; Forseth, R.R.; Bowers, A.A.; Schroeder, F.C.; Walsh, C.T. A backup plan for self-protection: S-methylation of holomycin biosynthetic intermediates in Streptomyces clavuligerus. ChemBioChem 2012, 13, 2521–2526. [Google Scholar] [CrossRef]
  59. Juhl, M.J.; Clark, D.P. Thiophene-degrading Escherichia coli mutants possess sulfone oxidase activity and show altered resistance to sulfur-containing antibiotics. Appl. Environ. Microbiol. 1990, 56, 3179–3185. [Google Scholar]
  60. Mariani, R.; Maffioli, S.I. Bacterial RNA Polymerase Inhibitors: An Organized Overview of their Structure, Derivatives, Biological Activity and Current Clinical Development Status. Curr. Med. Chem. 2009, 16, 430–454. [Google Scholar] [CrossRef]
  61. Floss, H.G.; Yu, T.W. Rifamycin-mode of action, resistance, and biosynthesis. Chem. Rev. 2005, 105, 621–632. [Google Scholar] [CrossRef]
  62. Schmidt, U.; Geiger, F. Total Synthesis of the Antibiotics Thiolutin, Aureothricin, and Holomycin. Angew. Chem. Int. Ed. 1962, 1, 265. [Google Scholar]
  63. Buchi, G.; Lukas, G. A total synthesis of holomycin. J. Am. Chem. Soc. 1964, 86, 5654–5658. [Google Scholar] [CrossRef]
  64. Hagio, K.; Yoneda, N. Total synthesis of holomycin, thiolutin, and aureothricin. Bull. Chem. Soc. Jpn. 1974, 47, 1484. [Google Scholar] [CrossRef]
  65. Ellis, J.E.; Fried, J.H.; Harrison, I.T.; Rapp, E.; Ross, C.H. Synthesis of holomycin and derivatives. J. Org. Chem. 1977, 42, 2891–2893. [Google Scholar] [CrossRef]
  66. Kishi, Y.; Fukuyama, T.; Nakatsuka, S. A new method for the synthesis of epidithiodiketopiperazines. J. Am. Chem. Soc. 1973, 95, 6490–6492. [Google Scholar] [CrossRef]
  67. Hjelmgaard, T.; Givskov, M.; Nielsen, J. Expedient total synthesis of pyrrothine natural products and analogs. Org. Biomol. Chem. 2007, 5, 344–348. [Google Scholar] [CrossRef]
  68. Stachel, H.D.; Nienaber, J.; Zoukas, T. Ring-fused 1,2-dithioles, I. Synthesis of thiolutine and related compounds. Ann. Chem. 1992, 5, 473–480. [Google Scholar]
  69. Stachel, H.D.; Eckl, E.; Immerz-Winkler, E.; Kreiner, C.; Weigand, W.; Robl, C.; Wunsch, R.; Dick, S.; Drescher, N. Synthesis and reactions of new dithiolopyrrolones. Helvetica Chimica Acta 2002, 85, 4453–4467. [Google Scholar] [CrossRef]
  70. Chen, G.; Guo, Y.; Li, B. Dithiolopyrrolones compounds and their therapeutic applications. Patent WO2008038175 A3, 12 June 2008. [Google Scholar]
  71. Li, B.; Lyle, M.P.A.; Chen, G.; Li, J.; Hu, K.; Tang, L.; Alaoui-Jamali, A.; Webster, J. Substituted 6-amino-4H-[1,2]dithiolo[4,3-b]pyrrol-5-ones: Synthesis, structure-activity relationships, and cytotoxic activity on selected human cancer cell lines. Bioorg. Med. Chem. 2007, 15, 4601–4608. [Google Scholar] [CrossRef]
  72. Gao, X.; Hall, D.G. Catalytic asymmetric synthesis of a potent thiomarinol antibiotic. J. Am. Chem. Soc. 2005, 127, 1628–1629. [Google Scholar] [CrossRef]
  73. Goss, R.J.M.; Shankar, S.; Fayad, A.A. The generation of “unNatural” products: Synthetic biology meets synthetic chemistry. Nat. Prod. Rep. 2012, 29, 870–889. [Google Scholar] [CrossRef]
  74. Cane, D.E.; Kudo, F.; Kinoshita, K.; Khosla, C. Precursor-directed biosynthesis: Biochemical basis of the remarkable selectivity of the erythromycin polyketide synthase towards unsaturated triketides. Chem. Biol. 2002, 9, 131–142. [Google Scholar] [CrossRef]
  75. Merrouche, R.; Bouras, N.; Coppel, Y.; Mathieu, F.; Monje, M.C.; Sabaou, N.; Lebrihi, A. Dithiolopyrrolone antibiotic formation induced by adding valeric acid to the culture broth of Saccarothrix algeriensis. J. Nat. Prod. 2010, 73, 1164–1166. [Google Scholar] [CrossRef]
  76. Merrouche, R.; Bouras, N.; Coppel, Y.; Mathieu, F.; Sabaou, N.; Lebrihi, A. New dithiolopyrrolone antibiotics induced by adding sorbic acid to the culture medium of Saccharothrix algeriensis NRRL B-24137. FEMS Microbiol. Lett. 2011, 318, 41–46. [Google Scholar] [CrossRef]
  77. Pacholec, M.; Freel Meyers, C.L.; Oberthur, M.; Kahne, D.; Walsh, C.T. Characterization of the aminocoumarin ligase SimL from the simocyclinone pathway and tandem incubation with NovM,P,N from the novobiocin pathway. Biochemistry 2005, 44, 4949–4956. [Google Scholar] [CrossRef]
  78. Okanishi, M.; Umezawa, H. Plasmids involved in antibiotic production in Streptomyces. In Genetics of the Actinomyetales; Freerksen, E, Tarnok, I, Thumin, J.H., Eds.; Gustav Fischer Verlag: Stuttgard, NY, USA, 1978; pp. 19–38. [Google Scholar]
  79. Furumai, T.; Takeda, K.; Okanishi, M. Function of plasmid in the production of aureothricin 1. Elimination of plasmids and alteration of phenotypes caused by protoplast regeneration in Streptomyces kasugaensis. J Antibiot. 1982, 35, 1367–1373. [Google Scholar] [CrossRef]
  80. Fuente, A.; Lorenzana, L.M.; Martin, J.F.; Liras, P. Mutants of Streptomyces clavuligerus with disruptions in different genes for clavulanic acid biosynthesis produce large amounts of holomycin: Possible cross-regulation of two unrelated secondary metabolic pathways. J. Bacteriol. 2002, 184, 6559–6565. [Google Scholar] [CrossRef]
  81. Chorin, A.C.; Bijeire, L.; Monje, M.C.; Baziard, G.; Lebrihi, A.; Mathieu, F. Expression of pyrrothine N-acyltransferase activities in Saccharothrix algeriensis NRRL B-24137: New insights into dithiolopyrrolone antibiotic biosynthetic pathway. J Appl. Microbiol. 2009, 107, 1751–1762. [Google Scholar] [CrossRef]
  82. Medema, M.H.; Trefzer, A.; Kovalchuk, A.; van den Berg, M.; Müller, U.; Heijne, W.; Wu, L.; Alam, M.T.; Ronning, C.M.; Nierman, W.C.; et al. The sequence of a 1.8-Mb bacterial linear plasmid reveals a rich evolutionary reservoir of secondary metabolic pathways. Genome Biol. Evol. 2010, 2, 212–224. [Google Scholar] [CrossRef]
  83. Li, B.; Walsh, C.T. Identification of the gene cluster for the dithiolopyrrolone antibiotic holomycin in Streptomyces clavuligerus. Proc. Natl. Acad. Sci. USA 2010, 107, 19731–19735. [Google Scholar] [CrossRef]
  84. Huang, S.; Zhao, Y.; Qin, Z.; Wang, X.; Onega, M.; Chen, L.; He, J.; Yu, Y.; Deng, H. Identification and heterologous expression of the biosynthetic gene cluster for holomycin produced by Streptomyces clavuligerus. Process Biochem. 2011, 46, 811–816. [Google Scholar] [CrossRef]
  85. Robles-Reglero, V.; Santamarta, I.; Alvarez-Álvarez, R.; Martín, J.F.; Liras, P. Transcriptional analysis and proteomics of the holomycin gene cluster in overproducer mutants of Streptomyces clavuligerus. J. Biotechnol. 2013, 163, 69–76. [Google Scholar] [CrossRef]
  86. Wang, C.; Wesener, S.R.; Zhang, H.; Cheng, Y.Q. An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide. Chem. Biol. 2009, 16, 585–593. [Google Scholar] [CrossRef]
  87. Fukuda, D.; Haines, A.S.; Song, Z.; Murphy, A.C.; Hothersall, J.; Stephens, E.R.; Gurney, R.; Cox, R.J.; Crosby, J.; Willis, C.L.; Simpson, J.T.; Thomas, C.M. A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic. PLoS One 2011, 6, e18031. [Google Scholar] [CrossRef]
  88. Scharf, D.H.; Remme, N.; Heinekamp, T.; Hortschansky, P.; Brakhage, A.A.; Hertweck, C. Transannular disulfide formation in gliotoxin biosynthesis and its role in self-resistance of the human pathogen Aspergillus fumigatus. J. Am. Chem. Soc. 2010, 132, 10136–10141. [Google Scholar] [CrossRef]
  89. Li, B.; Walsh, C.T. Streptomyces clavuligerus HlmI is an intramolecular disulfide-forming dithiol oxidase in holomycin biosynthesis. Biochemistry 2011, 50, 4615–4622. [Google Scholar] [CrossRef]
  90. Nárdiz, N.; Santamarta, I.; Lorenzana, L.M.; Martín, J.F.; Liras, P. A rhodanese-like protein is highly overrepresented in the mutant S. clavuligerus oppA2::aph: effect on holomycin and other secondary metabolites production. Microb. Biotechnol. 2011, 4, 216–225. [Google Scholar] [CrossRef]
  91. de la Fuente, A.; Martín, J.F.; Rodríguez-García, A.; Liras, P. Two proteins with ornithine acetyltransferase activity show different functions in Streptomyces clavuligerus: Oat2 modulates clavulanic acid biosynthesis in response to arginine. J. Bacteriol. 2004, 186, 6501–6507. [Google Scholar] [CrossRef]
  92. Liras, P.; Gomez-Escribano, J.P.; Santamarta, I. Regulatory mechanisms controlling antibiotic production in Streptomyces clavuligerus. J. Ind. Microbiol. Biotechnol. 2008, 35, 667–676. [Google Scholar] [CrossRef]
  93. Yin, H.; Xiang, S.; Zheng, J.; Fan, K.; Yu, T.; Yang, X.; Peng, Y.; Wang, H.; Feng, D.; Luo, Y.; Bai, H.; Yang, K. Induction of holomycin production and complex metabolic changes by the argR mutation in Streptomyces clavuligerus NP1. Appl. Environ. Microbiol. 2012, 78, 3431–3441. [Google Scholar] [CrossRef]
  94. Chen, L.; Wang, Y.; Guo, H.; Xu, M.; Deng, Z.; Tao, M. High-throughput screening for Streptomyces antibiotic biosynthesis activators. Appl. Environ. Microbiol. 2012, 78, 4526–4528. [Google Scholar] [CrossRef]
  95. Oh, D.C.; Kauffman, C.A.; Jensen, P.R.; Fenical, W. Induced production of emericellamides A and B from the marine-derived fungus Emericella sp. in competing co-culture. J. Nat. Prod. 2007, 70, 515–520. [Google Scholar] [CrossRef]
  96. Slattery, M.; Rajbhandari, I.; Wesson, K. Competition-mediated antibiotic induction in the marine bacterium Streptomyces tenjimariensis. Microb. Ecol. 2001, 41, 90–96. [Google Scholar]
  97. Charusanti, P.; Fong, N.L.; Nagarajan, H.; Pereira, A.R.; Li, H.J.; Abate, E.A.; Su, Y.; Gerwick, W.H.; Palsson, B.O. Exploiting adaptive laboratory evolution of Streptomyces clavuligerus for antibiotic discovery and overproduction. PLoS One 2012, 7, e33727. [Google Scholar]
  98. Condurso, H.L.; Bruner, S.D. Structure and noncanonical chemistry of nonribosomal peptide biosynthetic machinery. Nat. Prod. Rep. 2012, 29, 1099–1110. [Google Scholar] [CrossRef]
  99. Luft, T.; Li, S.M.; Scheible, H.; Kammerer, B.; Heide, L. Overexpression, purification and characterization of SimL, an amide synthetase involved in simocyclinone biosynthesis. Arch. Microbiol. 2005, 183, 277–285. [Google Scholar] [CrossRef]
  100. Steffensky, M.; Li, S.M.; Heide, L. Cloning, overexpression, and purification of novobiocic acid synthetase from Streptomyces spheroides NCIMB 11891. J. Biol. Chem. 2000, 275, 21754–21760. [Google Scholar] [CrossRef]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top